Page last updated: 2024-11-06

ethylhydrocupreine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ethylhydrocupreine: structure; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

optochin : A cinchona alkaloid consisting of 10,11-dihydrocinchonan bearing hydroxy and ethoxy substituents at positions 9 and 6' respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
CinchonagenusA genus of rubiaceous South American trees that yields the toxic CINCHONA ALKALOIDS from their bark; QUININE; QUINIDINE; chinconine, cinchonidine and others are used to treat MALARIA and CARDIAC ARRHYTHMIAS.[MeSH]RubiaceaeThe Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH]

Cross-References

ID SourceID
PubMed CID87880
CHEMBL ID548228
CHEBI ID86455
SCHEMBL ID467210
MeSH IDM0067991

Synonyms (37)

Synonym
hydrocinchonidine, 6'-ethoxy-
cinchonan-9-ol, 6'-ethoxy-10,11-dihydro-, (8-alpha,9r)-
optochin
hydrocupreine, o(sup 6')-ethyl-
einecs 208-333-5
hydrocupreine ethyl ether
optoquine
numoquin
brn 0092227
ethylhydrocupreine
TCMDC-125547 ,
CHEMBL548228
chebi:86455 ,
optichin
hydrocupreine, o6'-ethyl-
hydrocupreine, ethyl ether
gnf-pf-5532 ,
522-60-1
(r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol
(1r)((2s,4s,5r)-5-ethylquinuclidin-2-yl)(6-ethoxy(4-quinolyl))methan-1-ol
unii-4w030vs2og
4w030vs2og ,
4-23-00-03195 (beilstein handbook reference)
(8.alpha.,9r)-6'-ethoxy-10,11-dihydrocinchonan-9-ol
ethylhydrocupreine [mi]
cinchonan-9-ol, 6'-ethoxy-10,11-dihydro-, (8.alpha.,9r)-
SCHEMBL467210
(s)-(6-ethoxyquinolin-4-yl)({5-ethyl-1-azabicyclo[2.2.2]octan-2-yl})methanol
J-650218
(8alpha,9r)-6'-ethoxy-10,11-dihydrocinchonan-9-ol
SR-01000883742-1
sr-01000883742
ethylhydrocupreine, analytical standard
DTXSID50893924
(r)-(6-ethoxyquinolin-4-yl)((2s,4s,5r)-5-ethylquinuclidin-2-yl)methanol
CS-0129354
HY-136429

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitorAn EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that inhibits H(+)/K(+)-exchanging ATPase, EC 3.6.3.10. Such compounds are also known as proton pump inhibitors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cinchona alkaloidAn alkaloid based on a cinchonan skeleton.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID1602714Elimination half life in ICR mouse at 2.5 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602684Antibacterial activity against amoxicillin/penicillin/chloramphenicol/erythromycin/meropenem/cefotaxime-resistant Streptococcus pneumoniae TH2582 (19A) after 20 hrs by CLSI-based microdilution method2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1602675Antibacterial activity against Streptococcus pneumoniae D39 after 20 hrs by CLSI-based microdilution method2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602676Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602715Tmax in ICR mouse at 2.5 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602710Tmax in ICR mouse at 25 mg/kg, po via bolus administration by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602719Clearance in ICR mouse at 2.5 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602686Antibacterial activity against penicillin/erythromycin/meropenem/tetracycline-resistant Streptococcus pneumoniae TH2863 (19F) after 20 hrs by CLSI-based microdilution method2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602671Mitochondrial toxicity in human HepG2 cells assessed as reduction in cell viability after 24 hrs in presence of glucose by CellTiter-Glo assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602688Antibacterial activity against optochin-resistant Streptococcus pneumoniae R6 expressing atpE G145A mutant after 20 hrs by CLSI-based microdilution method2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602711Cmax in ICR mouse at 25 mg/kg, po via bolus administration by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602683Antibacterial activity against amoxicillin/penicillin/cefotaxime/erythromycin/tetracycline-resistant Streptococcus pneumoniae TH2784 (19F) after 20 hrs by CLSI-based microdilution method2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602717AUCt in ICR mouse at 2.5 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602681Antibacterial activity against Streptococcus pneumoniae R6 after 20 hrs by CLSI-based microdilution method2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602687Antibacterial activity against optochin-resistant Streptococcus pneumoniae R6 expressing atpE G142C mutant after 20 hrs by CLSI-based microdilution method2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602718Volume of distribution at steady state in ICR mouse at 2.5 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602669Mitochondrial toxicity in human HepG2 cells assessed as reduction in cell viability after 24 hrs in presence of galactose by CellTiter-Glo assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602712AUCt in ICR mouse at 25 mg/kg, po via bolus administration by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602677Bactericidal activity against Streptococcus pneumoniae D39 after 24 hrs2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1602670Elimination half life in ICR mouse at 25 mg/kg, po via bolus administration by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602716Cmax in ICR mouse at 2.5 mg/kg, iv by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602685Antibacterial activity against amoxicillin/penicillin/erythromycin/ertapenem/moxifloxacin/cefotaxime-resistant Streptococcus pneumoniae TH2889 (6B) after 20 hrs by CLSI-based microdilution method2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1602713Oral bioavailability in ICR mouse at 25 mg/kg via bolus administration by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1602720Drug metabolism in ICR mouse liver microsomes at 10 uM preincubated with NADPH for 10 mins and measured after 60 mins by LC-MS/MS analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (65)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (24.62)18.7374
1990's8 (12.31)18.2507
2000's23 (35.38)29.6817
2010's15 (23.08)24.3611
2020's3 (4.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.38 (24.57)
Research Supply Index4.23 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index70.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies5 (7.35%)4.05%
Observational0 (0.00%)0.25%
Other63 (92.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]